Pre-clinical development of Listeria-based nanovaccines as immunotherapies for solid tumours: insights from melanoma-Reference-Cited by-同舟云学术

Pre-clinical development of Listeria-based nanovaccines as immunotherapies for solid tumours: insights from melanoma

Published:2018-11-10 Issue:2 Volume:8 Page:e1541534
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Terán-Navarro Hector¹,Calderon-Gonzalez Ricardo¹^ORCID,Salcines-Cuevas David¹^ORCID,García Isabel²,Marradi Marco²^ORCID,Freire Javier³,Salmon Erwan¹,Portillo-Gonzalez Mar¹^ORCID,Frande-Cabanes Elisabet¹^ORCID,García-Castaño Almudena⁴,Martinez-Callejo Virginia⁵,Gomez-Roman Javier³,Tobes Raquel⁶^ORCID,Rivera Fernando⁴,Yañez-Diaz Sonsoles¹⁷,Álvarez-Domínguez Carmen¹

Affiliation:

1. Group of Listeria based Nanovaccines and cellular vaccines and their applications in biomedicine, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Cantabria, Spain

2. Bionanoplasmonics Laboratory, CIC biomaGUNE and Biomedical Research Networking Center in Bioengineering, Nanomaterials and Nanomedicine (CIBER-BBN), Donostia-San Sebastián, Gipuzkoa, Spain

3. Servicio de Anatomía Patológica, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain

4. Servicio de Oncología Médica, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain

5. Servicio de Farmacia Hospitalaria, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain

6. Oh no Sequences! Research Group, Era7 Bioinformatics, Granada, Andalucia, Spain

7. Servicio de Dermatología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain

Funder

IDIVAL

MINECO

ISCIII

LPLV

FIPSE

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1541534

Reference50 articles.

1. Collision of Pigmented Benign Tumours: A Possible Simulator of Melanoma

2. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

3. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

4. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanovaccines: Immunogenic tumor antigens, targeted delivery, and combination therapy to enhance cancer immunotherapy;Drug Development Research;2024-08

2. Peptide nanovaccine in melanoma immunotherapy;International Immunopharmacology;2024-03

3. Gold Nanoparticles: Construction for Drug Delivery and Application in Cancer Immunotherapy;Pharmaceutics;2023-07-02

4. New advances in pharmaceutical strategies for sensitizing anti‐PD ‐1 immunotherapy and clinical research;WIREs Nanomedicine and Nanobiotechnology;2022-08-05

5. Current Status and Future Directions of Bacteria-Based Immunotherapy;Frontiers in Immunology;2022-06-10